Galmed Pharmaceuticals is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.39 – an increase of 16.81% over the previous week. Galmed Pharmaceuticals employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.39 |
|---|---|
| 52-week range | $1.15 - $15.10 |
| 50-day moving average | $1.52 |
| 200-day moving average | $3.01 |
| Wall St. target price | $12.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-8.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.41 from 2025-05-22
| 1 week (2025-05-16) | 18.49% |
|---|---|
| 1 month (2025-04-24) | -12.96% |
| 3 months (2025-02-24) | -48.73% |
| 6 months (2024-11-22) | -48.73% |
| 1 year (2024-05-24) | 263.96% |
|---|---|
| 2 years (2023-05-24) | -97.68% |
| 3 years (2022-05-24) | 106.2 |
| 5 years (2020-05-22) | 1045.8002 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -22.34% |
| Return on equity TTM | -49.77% |
| Profit margin | 0% |
| Book value | $9.81 |
| Market Capitalization | $3.1 million |
TTM: trailing 12 months
We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.
Galmed Pharmaceuticals's shares were split on a 1:12 basis on 29 August 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galmed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Galmed Pharmaceuticals shares which in turn could have impacted Galmed Pharmaceuticals's share price.
Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $1.15 up to $15.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 0.491. This would suggest that Galmed Pharmaceuticals's shares are less volatile than average (for this exchange).
Galmed Pharmaceuticals Ltd. , a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.